LYON, France --- “New comers and emerging applications for oncology and infectious diseases are driving the growth of microfluidics IP”, announces Dr Brice Sagot, COO and co-founder of KnowMade. Indeed microfluidic technologies have brought numerous advantages in diagnostic applications. In its latest patent landscape report titled “Microfluidic Technologies for Diagnostic Applications”, KnowMade analyses the microfluidic patent landscape for diagnostic applications and lists the numerous benefits including smaller systems, smaller sample volume, near-patient technologies, reduced processing time and cost reduction.
According to KnowMade, the scope of diagnostic applications is very broad (cancers, genetic and neurodegenerative disorders, infectious diseases, diabetes and more) and microfluidic technology directly impacts therapeutic approaches by allowing a specific and quick detection and characterization of the disease as well as an easier evolution monitoring.
KnowMade’s analysts propose today an overview of this patent landscape with facts, figures, key players and more: who are the new comers? What are the leading applications? What are the keys to success?